APRE
- Aprea Therapeutics, Inc.
()
Overview
Company Summary
Aprea Therapeutics, Inc. (APRE) is a biopharmaceutical company that specializes in developing novel cancer treatment therapeutics. The company focuses specifically on targeting and restoring the tumor suppressor protein called p53, which plays a crucial role in preventing cancer cell growth.
APRE's innovative approach involves leveraging the unique capabilities of the p53 protein to induce programmed cell death, known as apoptosis, in cancer cells. By utilizing small molecules, APRE aims to reactivate and stabilize the p53 protein, which is often inactivated or mutated in many types of cancer.
The company's lead product candidate, known as eprenetapopt (APR-246), is in advanced stages of clinical development. Eprenetapopt has demonstrated promising results in combination with chemotherapy drugs and has shown potential in treating various types of cancers, including ovarian, lung, and myelodysplastic syndrome.
Through its research and development efforts, Aprea Therapeutics is dedicated to discovering and developing effective and targeted therapies for life-threatening cancers. The company's ultimate goal is to improve patient outcomes and provide much-needed treatment options for individuals battling cancer.